Search Results
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
Dr. Wierda on Using CD19-Targeted CAR T Cells in CLL
Findings for CD19-Targeted CAR T Cells in Combination With Ibrutinib in CLL
Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL
CAR T: CD19-Targeted Therapy in R/R DLBCL
Efficacy of bispecific CD19/CD22 CAR T-cells in B-cell malignancies
Feasibility of sequential treatment with CD19-targeted agents in patients with LBCL
Lymphoma: Overview of Chimeric Antigen Receptor (CAR) T cells
Phase I study of CD22-targeted CAR-T therapy in patients with CD19-negative B-ALL
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
Tafasitamab plus lenalidomide post-CD19 CAR-T is associated with poor outcomes in LBCL
Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells
